Theratechnologies to phase down preclinical oncology research activities

Theratechnologies announced that it will phase down its preclinical oncology research activities. “The phasing down of research activities is aligned with the company’s focus on its commercial business and will further optimize its organizational cost structure, pursuant to the goal of generating positive Adjusted EBITDA. These changes are expected to result in a restructuring charge of approximately $625,000 in cash charges related to severance and other expenses and approximately $770,000 in non-cash charges. The company anticipates all charges to be fully taken during 2024,” the company stated. The company will continue to prioritize its ongoing Phase 1 clinical trial of sudocetaxel zendusortide, TH1902, a novel peptide-drug conjugate, or PDC, in patients with advanced ovarian cancer. All figures below are in U.S. dollars. The company will continue to share accumulated preclinical data, including the presentation of two separate posters at the American Association for Cancer Research, or AACR, annual meeting, to be held April 5-9 in San Diego, Calif., one of which features data from new PDCs. “I am very proud of our exceptional research team, whose work has contributed greatly to the scientific discourse and understanding of advanced cancers. Our investment in the SORT1+ Technology platform over the past five years has generated important evidence on multiple peptide-drug conjugates with different payloads. Now that we have significantly advanced our preclinical program, we are well-positioned to leverage this wealth of data and insights to attract an oncology R&D partner,” said Paul Levesque, President and CEO at Theratechnologies.